- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Money laundering case: Surya Pharma properties worth Rs 185 crore attached by ED
PMLA Investigation revealed that the modus operandi of the said fraud was availing Letter of Credits (LCs) in lieu of bogus invoices and discounting these LCs by the associated entities.
New Delhi: The Directorate of Enforcement (ED) has attached properties worth Rs 185.1 crore belonging to Surya Pharmaceuticals Ltd in a money laundering case.
The attached properties include building, plant, and machinery, the ED said in a statement on Tuesday.
The enforcement agency has taken the action under the Prevention of Money Laundering Act (PMLA), 2002.
ED initiated an investigation under the provisions of PMLA, 2002 on the basis of 2 FIRs registered by CBI on the complaint of State Bank of India, Chandigarh, and Punjab and Sind Bank, Karnal against Surya Pharmaceuticals Ltd, its Managing Director Rajiv Goyal and others for defrauding the banks to the tune of Rs 828 crore.
PMLA Investigation further revealed that the modus operandi of the said fraud was availing Letter of Credits (LCs) in lieu of bogus invoices and discounting these LCs by the associated entities.
Through web of fraudulent transactions, they siphoned off the proceeds of the credit facilities taken from the banks and used for the purchase of various assets in the name of the company, individuals, and associated entities.
Medical Dialogues team had earlier reported that more than ₹ 20 crore worth of assets had been attached under the anti-money laundering law in the alleged bank fraud case against Gujarat-based pharmaceutical group Sterling Biotech.
Directorate of EnforcementSurya Pharmamoney launderingPrevention of Money Laundering Act 2022Punjab and Sind BankState Bank of IndiaSBI
Source : with inputsRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story